Eligibility of BC patients to HER2-targeted therapy depends on detection of HER2/ERBB2 overexpression/amplification in the tumor tissue by immunohistochemistry (IHC) and/or in situ hybridization (ISH). Here, ERBB2 is linked to neoplasm.